Search
forLearn
5 / 801 resultslearn RH410
learn panthenyl ethyl ether
learn ORPL
learn procapil
Research
5 / 1000+ resultsresearch CD34 and BerEP4 Are Helpful to Distinguish Basaloid Tricholemmoma From Basal Cell Carcinoma
BerEP4 and CD34 staining can help tell apart tricholemmoma from basal cell carcinoma.
research Ber‐EP4 antigen is a marker for a cell population related to the secondary hair germ
Ber‐EP4 marks cells related to the secondary hair germ in hair follicles.
research Human epithelial hair follicle stem cells and their progeny: Current state of knowledge, the widening gap in translational research and future challenges
We need more research to better understand human hair follicle stem cells for improved treatments for hair loss and skin cancer.
research British Society for Dermatopathology
Dermatologists give better information on pathology forms, hypersensitivity vasculitis is a common skin issue, misdiagnoses can occur, and various skin conditions are linked to loss of elastin or genetic factors.
research Colon Cancer Stem Cells: Promise of Targeted Therapy
Targeting colon cancer stem cells might lead to better treatment results.
Community Join
5 / 1000+ resultscommunity RU55481
community Shiseido RCH-01
Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.
community Has redensyl, procapil and baicapil worked for anyone?
Exploring treatments for hair loss, such as finasteride, minoxidil, RPB (an unknown acronym), vitamin D levels, and derma rolling.
community Replicel, worthy of hype or probable disappointment? Questions thread
The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.